PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
25533960-3	2015	The human OX2 receptor (OX2R) belongs to the beta branch of the rhodopsin family of GPCRs, and can bind to diverse compounds including the native agonist peptides orexin-A and orexin-B and the potent therapeutic inhibitor suvorexant.	suvorexant	222-232	hypocretin receptor 2	Homo sapiens	10-22
25969666-0	2015	Suvorexant: The first orexin receptor antagonist to treat insomnia.	suvorexant	0-10	hypocretin neuropeptide precursor	Homo sapiens	22-28
25969666-2	2015	A novel approach to treat insomnia has been introduced recently, with the approval of suvorexant, the first in a new class of orexin receptor antagonists.	suvorexant	86-96	hypocretin neuropeptide precursor	Homo sapiens	126-132
25533960-3	2015	The human OX2 receptor (OX2R) belongs to the beta branch of the rhodopsin family of GPCRs, and can bind to diverse compounds including the native agonist peptides orexin-A and orexin-B and the potent therapeutic inhibitor suvorexant.	suvorexant	222-232	hypocretin receptor 2	Homo sapiens	24-28
25291725-1	2014	Suvorexant is a pharmacologically novel dual antagonist of orexin receptors OX1R and OX2R, which has an effect that promotes sleep by reducing arousal and wakefulness.	suvorexant	0-10	hypocretin receptor 1	Homo sapiens	76-80
25397996-3	2015	Suvorexant helps in decreasing wakefulness by counteracting orexin activity.	suvorexant	0-10	hypocretin neuropeptide precursor	Homo sapiens	60-66
25227290-1	2014	Suvorexant (Belsomra( )), a first-in-class, orally active dual orexin-1 receptor and orexin-2 receptor antagonist, has been developed by Merck for the treatment of insomnia.	suvorexant	0-10	hypocretin neuropeptide precursor	Homo sapiens	63-69
25227290-1	2014	Suvorexant (Belsomra( )), a first-in-class, orally active dual orexin-1 receptor and orexin-2 receptor antagonist, has been developed by Merck for the treatment of insomnia.	suvorexant	0-10	hypocretin neuropeptide precursor	Homo sapiens	85-91
25291725-1	2014	Suvorexant is a pharmacologically novel dual antagonist of orexin receptors OX1R and OX2R, which has an effect that promotes sleep by reducing arousal and wakefulness.	suvorexant	0-10	hypocretin receptor 2	Homo sapiens	85-89
23359095-6	2013	Indeed, phase III clinical trials were completed last year of suvorexant, a non-selective (dual) antagonist for orexin receptors, for the treatment of primary insomnia, and demonstrate promising results.	suvorexant	62-72	hypocretin neuropeptide precursor	Homo sapiens	112-118
25197807-1	2014	STUDY OBJECTIVES: Suvorexant, an orexin receptor antagonist, improves sleep in healthy subjects (HS) and patients with insomnia.	suvorexant	18-28	hypocretin neuropeptide precursor	Homo sapiens	33-39
24680372-1	2014	BACKGROUND: Suvorexant (MK-4305) is an orexin receptor antagonist shown to be efficacious for insomnia over 3 months.	suvorexant	12-22	hypocretin neuropeptide precursor	Homo sapiens	39-45
24680372-1	2014	BACKGROUND: Suvorexant (MK-4305) is an orexin receptor antagonist shown to be efficacious for insomnia over 3 months.	suvorexant	24-31	hypocretin neuropeptide precursor	Homo sapiens	39-45
24592206-3	2014	The filing to FDA of the dual-activity orexin receptor antagonist (DORA) suvorexant for the indication of insomnia further corroborates the robustness of such evidences.	suvorexant	73-83	hypocretin neuropeptide precursor	Homo sapiens	39-45
23382047-7	2013	These results establish that p38 signaling is critical for SUV-induced skin carcinogenesis.	suvorexant	59-62	mitogen-activated protein kinase 14	Mus musculus	29-32
23024835-1	2012	Suvorexant is a dual orexin antagonist currently in Phase III clinical trials for the modulation of sleep and is being developed by Merck.	suvorexant	0-10	hypocretin neuropeptide precursor	Homo sapiens	21-27
22725839-1	2012	A concise, enantioselective synthesis of the potent dual orexin inhibitor suvorexant (1) is reported.	suvorexant	74-84	hypocretin neuropeptide precursor	Homo sapiens	57-63
22920041-4	2012	Merck"s suvorexant (MK-4305) is the first compound of the so-called dual orexin receptor antagonist (DORA) class expected to be submitted for FDA approval, with a new drug application anticipated in 2012.	suvorexant	8-18	hypocretin neuropeptide precursor	Homo sapiens	73-79
22920041-4	2012	Merck"s suvorexant (MK-4305) is the first compound of the so-called dual orexin receptor antagonist (DORA) class expected to be submitted for FDA approval, with a new drug application anticipated in 2012.	suvorexant	20-27	hypocretin neuropeptide precursor	Homo sapiens	73-79
21528938-0	2011	Reaction development and mechanistic study of a ruthenium catalyzed intramolecular asymmetric reductive amination en route to the dual Orexin inhibitor Suvorexant (MK-4305).	suvorexant	152-162	hypocretin neuropeptide precursor	Homo sapiens	135-141
21528938-0	2011	Reaction development and mechanistic study of a ruthenium catalyzed intramolecular asymmetric reductive amination en route to the dual Orexin inhibitor Suvorexant (MK-4305).	suvorexant	164-171	hypocretin neuropeptide precursor	Homo sapiens	135-141
21528938-1	2011	The first example of an intramolecular asymmetric reductive amination of a dialkyl ketone with an aliphatic amine has been developed for the synthesis of Suvorexant (MK-4305), a potent dual Orexin antagonist under development for the treatment of sleep disorders.	suvorexant	154-164	hypocretin neuropeptide precursor	Homo sapiens	190-196
21528938-1	2011	The first example of an intramolecular asymmetric reductive amination of a dialkyl ketone with an aliphatic amine has been developed for the synthesis of Suvorexant (MK-4305), a potent dual Orexin antagonist under development for the treatment of sleep disorders.	suvorexant	166-173	hypocretin neuropeptide precursor	Homo sapiens	190-196
34497544-3	2021	The present study examined the utility of magnetic resonance spectroscopy (MRS) for detecting neural and/or glial changes in the VTA to distinguish responders from non-responders before treatment with the orexin receptor antagonist suvorexant.	suvorexant	232-242	hypocretin neuropeptide precursor	Homo sapiens	205-211
21473737-4	2011	Suvorexant (MK-4305) is a potent, selective, and orally bioavailable antagonist of OX(1)R and OX(2)R currently under clinical investigation as a novel therapy for insomnia.	suvorexant	0-10	hypocretin receptor 1	Rattus norvegicus	83-89
21473737-4	2011	Suvorexant (MK-4305) is a potent, selective, and orally bioavailable antagonist of OX(1)R and OX(2)R currently under clinical investigation as a novel therapy for insomnia.	suvorexant	0-10	hypocretin receptor 2	Rattus norvegicus	94-100
21473737-4	2011	Suvorexant (MK-4305) is a potent, selective, and orally bioavailable antagonist of OX(1)R and OX(2)R currently under clinical investigation as a novel therapy for insomnia.	suvorexant	12-19	hypocretin receptor 1	Rattus norvegicus	83-89
21473737-4	2011	Suvorexant (MK-4305) is a potent, selective, and orally bioavailable antagonist of OX(1)R and OX(2)R currently under clinical investigation as a novel therapy for insomnia.	suvorexant	12-19	hypocretin receptor 2	Rattus norvegicus	94-100
34933185-5	2021	We, therefore, examined whether a dual orexin receptor antagonist, suvorexant, administered following evening exposure sessions, would enhance their therapeutic effectiveness for PTSD.	suvorexant	67-77	hypocretin neuropeptide precursor	Homo sapiens	39-45
32669442-3	2020	The nonselective orexin receptor antagonist suvorexant has been the first drug on the market targeting the orexin system and is prescribed for the treatment of insomnia.	suvorexant	44-54	hypocretin neuropeptide precursor	Homo sapiens	17-23
34989064-6	2022	The non-selective OX1 - and OX2 -receptor antagonist MK-4305 (suvorexant, 500.0 pg, 2.5 and 5.0 ng) enhanced dopamine efflux.	suvorexant	53-60	CD200 receptor 1	Rattus norvegicus	28-41
34989064-7	2022	A 2-h tetrodotoxin infusion into nucleus accumbens through the probe or co-administration of orexin-A (500.0 pg) strongly inhibited MK-4305 (5.0 ng)-induced accumbal dopamine efflux.	suvorexant	132-139	hypocretin neuropeptide precursor	Rattus norvegicus	93-101
33609365-3	2021	The orexin receptor antagonist suvorexant promotes sleep by blocking both OX1R and OX2R.	suvorexant	31-41	hypocretin (orexin) receptor 1	Mus musculus	74-78
33609365-3	2021	The orexin receptor antagonist suvorexant promotes sleep by blocking both OX1R and OX2R.	suvorexant	31-41	hypocretin (orexin) receptor 2	Mus musculus	83-87
35022783-2	2022	We tested the efficacy of the dual orexin receptor antagonist suvorexant for chronic insomnia related to nighttime VMS.	suvorexant	62-72	hypocretin neuropeptide precursor	Homo sapiens	35-41
33212086-14	2021	Additionally, suvorexant ameliorated the extrahypothalamic induced upregulation of CRH-R1 in SRS-exposed rats.	suvorexant	14-24	corticotropin releasing hormone receptor 1	Rattus norvegicus	83-89
30810914-2	2019	As suvorexant is metabolized primarily by Cytochrome P450 3A (CYP3A), and its pharmacokinetics may be affected by CYP3A modulators, the effects of CYP3A inhibitors (ketoconazole or diltiazem) or an inducer (rifampin [rifampicin]) on the pharmacokinetics, safety, and tolerability of suvorexant were investigated.	suvorexant	3-13	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	42-60
32224066-3	2020	Our recent research revealed that suvorexant, a dual orexin receptor antagonist, could improve behavioral circadian rhythm disorders in 9-month-old APP/PS1 mice.	suvorexant	34-44	hypocretin neuropeptide precursor	Homo sapiens	53-59
32224066-3	2020	Our recent research revealed that suvorexant, a dual orexin receptor antagonist, could improve behavioral circadian rhythm disorders in 9-month-old APP/PS1 mice.	suvorexant	34-44	presenilin 1	Mus musculus	152-155
32224066-4	2020	Here we further observed whether suvorexant could ameliorate the cognitive decline in APP/PS1 mice by using behavioral tests, and investigated the possible mechanisms by in vivo electrophysiological recording, western blot, and immunochemistry.	suvorexant	33-43	presenilin 1	Mus musculus	90-93
33224245-0	2020	Suvorexant, a Dual Orexin Receptor Antagonist, Protected Seizure through Interaction with GABAA and Glutamate Receptors.	suvorexant	0-10	hypocretin	Mus musculus	19-25
33224245-0	2020	Suvorexant, a Dual Orexin Receptor Antagonist, Protected Seizure through Interaction with GABAA and Glutamate Receptors.	suvorexant	0-10	gamma-aminobutyric acid (GABA) A receptor, subunit gamma 1	Mus musculus	90-95
31845549-12	2020	The OX1 and OX2 receptor antagonist MK-4305 and OX2 receptor antagonist EMPA, but not the OX1 receptor antagonist SB 334867, each counteracted orexin-A-induced inhibition of KCl-provoked increases in relative fluorescence intensity.	suvorexant	36-43	CD200 receptor 1	Rattus norvegicus	12-24
31845549-12	2020	The OX1 and OX2 receptor antagonist MK-4305 and OX2 receptor antagonist EMPA, but not the OX1 receptor antagonist SB 334867, each counteracted orexin-A-induced inhibition of KCl-provoked increases in relative fluorescence intensity.	suvorexant	36-43	hypocretin neuropeptide precursor	Rattus norvegicus	143-151
30810914-2	2019	As suvorexant is metabolized primarily by Cytochrome P450 3A (CYP3A), and its pharmacokinetics may be affected by CYP3A modulators, the effects of CYP3A inhibitors (ketoconazole or diltiazem) or an inducer (rifampin [rifampicin]) on the pharmacokinetics, safety, and tolerability of suvorexant were investigated.	suvorexant	3-13	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	62-67
30810914-2	2019	As suvorexant is metabolized primarily by Cytochrome P450 3A (CYP3A), and its pharmacokinetics may be affected by CYP3A modulators, the effects of CYP3A inhibitors (ketoconazole or diltiazem) or an inducer (rifampin [rifampicin]) on the pharmacokinetics, safety, and tolerability of suvorexant were investigated.	suvorexant	3-13	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	114-119
30810914-2	2019	As suvorexant is metabolized primarily by Cytochrome P450 3A (CYP3A), and its pharmacokinetics may be affected by CYP3A modulators, the effects of CYP3A inhibitors (ketoconazole or diltiazem) or an inducer (rifampin [rifampicin]) on the pharmacokinetics, safety, and tolerability of suvorexant were investigated.	suvorexant	3-13	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	114-119
30905886-3	2019	The orexin receptor antagonist suvorexant, which specifically block the endogenous waking system, has been approved as a new drug to treat insomnia.	suvorexant	31-41	hypocretin	Mus musculus	4-10
30895461-0	2019	Correction to: Effect of CYP3A Inhibition and Induction on the Pharmacokinetics of Suvorexant: Two Phase I, Open-Label, Fixed-Sequence Trials in Healthy Subjects.	suvorexant	83-93	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	25-30
28419646-0	2018	Suvorexant, an orexin/hypocretin receptor antagonist, attenuates motivational and hedonic properties of cocaine.	suvorexant	0-10	hypocretin neuropeptide precursor	Rattus norvegicus	15-21
30619717-2	2019	We investigated suvorexant (an anti-insomnia drug that targets the orexin system) effects on sleep architecture and glucose metabolism in T2DM patients with insomnia.	suvorexant	16-26	hypocretin neuropeptide precursor	Homo sapiens	67-73
29289556-8	2018	Hyper-activation of the orexin system also causes sleep disturbances, such as insomnia, and hence, suvorexant, an orexin receptor antagonist, has been clinically used to treat insomnia.	suvorexant	99-109	hypocretin neuropeptide precursor	Homo sapiens	24-30
29289556-8	2018	Hyper-activation of the orexin system also causes sleep disturbances, such as insomnia, and hence, suvorexant, an orexin receptor antagonist, has been clinically used to treat insomnia.	suvorexant	99-109	hypocretin neuropeptide precursor	Homo sapiens	114-120
29450984-4	2018	By comparison with the wild type of OX2 R, the results show the 1,2,3-triazole and p-toluamide groups of suvorexant are changed in the N324A mutant of OX2 R during 200 ns MD simulations.	suvorexant	105-115	hypocretin receptor 2	Homo sapiens	36-41
29450984-4	2018	By comparison with the wild type of OX2 R, the results show the 1,2,3-triazole and p-toluamide groups of suvorexant are changed in the N324A mutant of OX2 R during 200 ns MD simulations.	suvorexant	105-115	hypocretin receptor 2	Homo sapiens	151-156
29450984-5	2018	The QM/MM and weak interaction analysis are employed to calculate the non-covalent bonds interaction between suvorexant and key residues in the wild type and N324A mutant of OX2 R.	suvorexant	109-119	hypocretin receptor 2	Homo sapiens	174-179
28741623-0	2018	Effects of Suvorexant, a Dual Orexin/Hypocretin Receptor Antagonist, on Impulsive Behavior Associated with Cocaine.	suvorexant	11-21	hypocretin neuropeptide precursor	Rattus norvegicus	30-36
28741623-7	2018	Suvorexant, a dual (OX1/2R) orexin receptor antagonist, reduced cocaine-evoked premature responses in 5-CSRTT when administered systemically or directly into VTA.	suvorexant	0-10	hypocretin neuropeptide precursor	Rattus norvegicus	28-34
28741623-9	2018	Finally, suvorexant did not alter Fos-immunoreactivity within tyrosine hydroxylase-immunolabeled neurons of VTA, but did attenuate cocaine- and orexin-induced increases in calcium transient amplitude within neurons of VTA.	suvorexant	9-19	hypocretin neuropeptide precursor	Rattus norvegicus	144-150
28419646-3	2018	Suvorexant, a dual orexin receptor antagonist, recently received approval from the US Food and Drug Administration to treat insomnia.	suvorexant	0-10	hypocretin neuropeptide precursor	Rattus norvegicus	19-25
28993579-9	2017	The OX1 and OX2 receptor antagonist MK-4305, but not the OX1 receptor antagonist SB334867, counteracted the effects of orexin-A on the KCl-induced increase in F/F0.	suvorexant	36-43	CD200 receptor 1	Rattus norvegicus	12-24
28993579-9	2017	The OX1 and OX2 receptor antagonist MK-4305, but not the OX1 receptor antagonist SB334867, counteracted the effects of orexin-A on the KCl-induced increase in F/F0.	suvorexant	36-43	hypocretin neuropeptide precursor	Rattus norvegicus	119-127
28212694-0	2017	Suvorexant-Induced Dream Enactment Behavior in Parkinson Disease: A Case Report.	suvorexant	0-10	potassium voltage-gated channel interacting protein 3	Homo sapiens	19-24
28447885-9	2017	Last, administration of the dual orexin receptor antagonist, suvorexant, during the initial 24 h post-resuscitation, led to sustained neurological deficits.	suvorexant	61-71	hypocretin neuropeptide precursor	Rattus norvegicus	33-39
28994603-4	2017	By blocking orexin receptors, suvorexant induces sleep.	suvorexant	30-40	hypocretin neuropeptide precursor	Homo sapiens	12-18
28945327-0	2017	Suvorexant as an orexin antagonist may regulate serum glucose levels in psychiatric patients with insomnia.	suvorexant	0-10	hypocretin neuropeptide precursor	Homo sapiens	17-23
28778226-3	2017	Although hypocretin receptor antagonists have been developed as sleep-inducing drugs, a high dose of suvorexant, a hypocretin receptor antagonist, inhibits gene expression of prepro-hypocretin to induce narcoleptic attack in wild-type mice.	suvorexant	101-111	hypocretin	Mus musculus	9-19
28778226-3	2017	Although hypocretin receptor antagonists have been developed as sleep-inducing drugs, a high dose of suvorexant, a hypocretin receptor antagonist, inhibits gene expression of prepro-hypocretin to induce narcoleptic attack in wild-type mice.	suvorexant	101-111	hypocretin	Mus musculus	115-125
28778226-3	2017	Although hypocretin receptor antagonists have been developed as sleep-inducing drugs, a high dose of suvorexant, a hypocretin receptor antagonist, inhibits gene expression of prepro-hypocretin to induce narcoleptic attack in wild-type mice.	suvorexant	101-111	hypocretin	Mus musculus	115-125
28584695-0	2017	Neuroendocrine, Autonomic, and Metabolic Responses to an Orexin Antagonist, Suvorexant, in Psychiatric Patients with Insomnia.	suvorexant	76-86	hypocretin neuropeptide precursor	Homo sapiens	57-63
27860547-0	2017	The Discovery of Suvorexant, the First Orexin Receptor Drug for Insomnia.	suvorexant	17-27	hypocretin neuropeptide precursor	Homo sapiens	39-45
27909991-6	2017	The orexin (hypocretin) neuropeptide system is an attractive target, given the recent FDA and PMDA approval of suvorexant for the treatment of insomnia.	suvorexant	111-121	hypocretin neuropeptide precursor	Homo sapiens	4-10
26864332-2	2016	Suvorexant (MK-4305, Belsomra ) is a first-in-class dual orexin receptor antagonist approved in the USA and Japan for the treatment of insomnia.	suvorexant	0-10	hypocretin neuropeptide precursor	Homo sapiens	57-63
27631554-2	2016	To investigate this possibility, we here examined the effects of suvorexant, an antiinsomnia drug targeting the orexin system, on sleep and glucose metabolism in type 2 diabetic mice.	suvorexant	65-75	hypocretin	Mus musculus	112-118
27390287-1	2016	Starting from suvorexant (trade name Belsomra), we successfully identified interesting templates leading to potent dual orexin receptor antagonists (DORAs) via a scaffold-hopping approach.	suvorexant	14-24	hypocretin neuropeptide precursor	Homo sapiens	120-126
26864332-2	2016	Suvorexant (MK-4305, Belsomra ) is a first-in-class dual orexin receptor antagonist approved in the USA and Japan for the treatment of insomnia.	suvorexant	12-19	hypocretin neuropeptide precursor	Homo sapiens	57-63
26864332-12	2016	In vitro, suvorexant demonstrated reversible inhibition of CYP3A4 and 2C19 (IC50 ~ 4-5 muM), and weak time-dependent inhibition of CYP3A4 (KI = 12 muM, kinact = 0.14 min(-1)).	suvorexant	10-20	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	59-74
26864332-12	2016	In vitro, suvorexant demonstrated reversible inhibition of CYP3A4 and 2C19 (IC50 ~ 4-5 muM), and weak time-dependent inhibition of CYP3A4 (KI = 12 muM, kinact = 0.14 min(-1)).	suvorexant	10-20	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	59-65
26864332-13	2016	Suvorexant was also a weak inducer of CYP3A4, 1A2 and 2B6.	suvorexant	0-10	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	38-44
27191770-8	2016	DISCUSSION: Because suvorexant is metabolized by CYP3A4, next-day somnolence could have occurred as a result of increased plasma suvorexant concentration due to CYP3A4 inhibition by diltiazem.	suvorexant	20-30	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	49-55
27191770-8	2016	DISCUSSION: Because suvorexant is metabolized by CYP3A4, next-day somnolence could have occurred as a result of increased plasma suvorexant concentration due to CYP3A4 inhibition by diltiazem.	suvorexant	20-30	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	161-167
27191770-8	2016	DISCUSSION: Because suvorexant is metabolized by CYP3A4, next-day somnolence could have occurred as a result of increased plasma suvorexant concentration due to CYP3A4 inhibition by diltiazem.	suvorexant	129-139	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	161-167
26648692-5	2015	Suvorexant is metabolized by the hepatic CYP3A system and should be avoided in combination with strong CYP3A inhibitors.	suvorexant	0-10	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	41-46
26317591-5	2016	The work described herein culminated in the 2014 FDA approval of suvorexant as a first-in-class dual orexin receptor antagonist for the treatment of insomnia.	suvorexant	65-75	hypocretin neuropeptide precursor	Homo sapiens	101-107
27253658-0	2016	Assessment of the Abuse Potential of the Orexin Receptor Antagonist, Suvorexant, Compared With Zolpidem in a Randomized Crossover Study.	suvorexant	69-79	hypocretin neuropeptide precursor	Homo sapiens	41-47
27253658-1	2016	Suvorexant is a dual orexin receptor antagonist approved in the United States and Japan for the treatment of insomnia at a maximum dose of 20 mg.	suvorexant	0-10	hypocretin neuropeptide precursor	Homo sapiens	21-27
26950369-3	2016	We determined structures of hOX1R bound to the OX1R-selective antagonist SB-674042 and the dual antagonist suvorexant at 2.8-A and 2.75-A resolution, respectively, and used molecular modeling to illuminate mechanisms of antagonist subtype selectivity between hOX1R and hOX2R.	suvorexant	107-117	hypocretin receptor 1	Homo sapiens	28-33
26950369-3	2016	We determined structures of hOX1R bound to the OX1R-selective antagonist SB-674042 and the dual antagonist suvorexant at 2.8-A and 2.75-A resolution, respectively, and used molecular modeling to illuminate mechanisms of antagonist subtype selectivity between hOX1R and hOX2R.	suvorexant	107-117	hypocretin receptor 1	Homo sapiens	29-33
26648692-5	2015	Suvorexant is metabolized by the hepatic CYP3A system and should be avoided in combination with strong CYP3A inhibitors.	suvorexant	0-10	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	103-108